Literature DB >> 16489364

Medicinal chemical properties of successful central nervous system drugs.

Hassan Pajouhesh1, George R Lenz.   

Abstract

Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the blood-brain barrier affinity and exhibit CNS activity. Factors relevant to the success of CNS drugs are reviewed. CNS drugs show values of molecular weight, lipophilicity, and hydrogen bond donor and acceptor that in general have a smaller range than general therapeutics. Pharmacokinetic properties can be manipulated by the medicinal chemist to a significant extent. The solubility, permeability, metabolic stability, protein binding, and human ether-ago-go-related gene inhibition of CNS compounds need to be optimized simultaneously with potency, selectivity, and other biological parameters. The balance between optimizing the physiochemical and pharmacokinetic properties to make the best compromises in properties is critical for designing new drugs likely to penetrate the blood brain barrier and affect relevant biological systems. This review is intended as a guide to designing CNS therapeutic agents with better drug-like properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16489364      PMCID: PMC1201314          DOI: 10.1602/neurorx.2.4.541

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  57 in total

Review 1.  Prediction of intestinal absorption and blood-brain barrier penetration by computational methods.

Authors:  D E Clark
Journal:  Comb Chem High Throughput Screen       Date:  2001-09       Impact factor: 1.339

2.  Characteristic physical properties and structural fragments of marketed oral drugs.

Authors:  Michal Vieth; Miles G Siegel; Richard E Higgs; Ian A Watson; Daniel H Robertson; Kenneth A Savin; Gregory L Durst; Philip A Hipskind
Journal:  J Med Chem       Date:  2004-01-01       Impact factor: 7.446

3.  Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates.

Authors:  Marc Adenot; Roger Lahana
Journal:  J Chem Inf Comput Sci       Date:  2004 Jan-Feb

Review 4.  The many roles of computation in drug discovery.

Authors:  William L Jorgensen
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

5.  Time-related differences in the physical property profiles of oral drugs.

Authors:  Paul D Leeson; Andrew M Davis
Journal:  J Med Chem       Date:  2004-12-02       Impact factor: 7.446

Review 6.  Structure, function, and regulation of cellular tight junctions.

Authors:  E E Schneeberger; R D Lynch
Journal:  Am J Physiol       Date:  1992-06

7.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?

Authors:  A Ajay; W P Walters; M A Murcko
Journal:  J Med Chem       Date:  1998-08-27       Impact factor: 7.446

8.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

Review 9.  T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevance.

Authors:  S I Ertel; E A Ertel; J P Clozel
Journal:  Cardiovasc Drugs Ther       Date:  1997-12       Impact factor: 3.727

Review 10.  A new look at lipid-membrane structure in relation to drug research.

Authors:  O G Mouritsen; K Jørgensen
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

View more
  264 in total

1.  Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Authors:  Adam L Green; Shakti H Ramkissoon; Dilara McCauley; Kristen Jones; Jennifer A Perry; Jessie Hao-Ru Hsu; Lori A Ramkissoon; Cecile L Maire; Benjamin Hubbell-Engler; David S Knoff; Sharon Shacham; Keith L Ligon; Andrew L Kung
Journal:  Neuro Oncol       Date:  2014-11-02       Impact factor: 12.300

2.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

Review 3.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

4.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

Authors:  Travis T Wager; Ramalakshmi Y Chandrasekaran; Xinjun Hou; Matthew D Troutman; Patrick R Verhoest; Anabella Villalobos; Yvonne Will
Journal:  ACS Chem Neurosci       Date:  2010-03-25       Impact factor: 4.418

5.  Anticancer potential of aminomethylidene-diazinanes I. Synthesis of arylaminomethylidene of diazinetriones and its cytotoxic effects tested in glioblastoma cells.

Authors:  Nichole A Pianovich; Mathew Dean; Adam Lassak; Krzysztof Reiss; Branko S Jursic
Journal:  Bioorg Med Chem       Date:  2017-08-12       Impact factor: 3.641

6.  Identification of thieno[3,2-b]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses.

Authors:  Weiping Peng; Daniel C Peltier; Martha J Larsen; Paul D Kirchhoff; Scott D Larsen; Richard R Neubig; David J Miller
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

7.  Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents.

Authors:  Benjamin J Josey; Elizabeth S Inks; Xuejun Wen; C James Chou
Journal:  J Med Chem       Date:  2013-01-30       Impact factor: 7.446

Review 8.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

9.  Radiosynthesis and evaluation of a fluorine-18 labeled radioligand targeting vesicular acetylcholine transporter.

Authors:  Xuyi Yue; Zonghua Luo; Hui Liu; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Bioorg Med Chem Lett       Date:  2018-09-24       Impact factor: 2.823

10.  Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.

Authors:  Hong Zhao; Guangxu Jin; Kemi Cui; Ding Ren; Timothy Liu; Peikai Chen; Solomon Wong; Fuhai Li; Yubo Fan; Angel Rodriguez; Jenny Chang; Stephen T C Wong
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.